Product information

From Health Canada

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Cancelled Post Market

Current status date:

2022-05-10

Original market date: See footnote 1

2007-10-17

Lot number: See footnote 2

35349063B

Expiry date: See footnote 2

2020-06-30

Product name:

TEVA-LISINOPRIL (TYPE P)

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

DIN:

02285088

Product Monograph/Veterinary Labelling:

Date: 2022-04-12 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company:

TEVA CANADA LIMITED
30 Novopharm Court
Toronto
Ontario
Canada M1B 2K9

Class:

Human

Dosage form(s):

Tablet

Route(s) of administration:

Oral

Number of active ingredient(s):

1

Schedule(s):

Prescription

 

American Hospital Formulary Service (AHFS): See footnote 3

24:32.04 

Anatomical Therapeutic Chemical (ATC): See footnote 4

C09AA03 LISINOPRIL

Active ingredient group (AIG) number:See footnote5

0121550001

List of active ingredient(s)
Active ingredient(s) Strength
LISINOPRIL 10 MG
Version 4.0.2
Date modified: